The first human conception resulting from a donated egg occurred in July of 1983, thirty years ago this month. Since that time thousands of children have been born from donated eggs, and as many women have become egg donors. Although clinics that specialize in assisted reproductive technologies (ARTs) operate, in many senses, according to medical standards of practice, I will argue that there are relevant differences between the norms of practice in the “regular” medical context and the norms of practice in the contexts of several newly emergent and emerging medical technologies. In this talk I focus on assisted reproductive technologies, and specifically on human egg donation, taking the salient features of human egg donation to apply by analogy to several other ARTs and possibly to emerging medical technologies in general. This presentation will focus on the norms of practice in the infertility clinic context as compared both to medical and business contexts. My intent is to identify potential sources of concern within the context of clinical egg donation that might arise due to the practice functioning on a business model rather than a medical model. This is not to say that medicine and business can be easily prised apart. However, there are certain norms of practice standardly operative in the medical context that we ought to expect would apply in the case of egg donation, but which do not. In particular, areas of clinical egg donation that might benefit from examination include recruitment and advertising, regulatory oversight, and institutional habits and structures considered smart business practice.